| Data | Hora | Fonte | Título | Código | Companhia |
| 30/05/2008 | 17:05 | Edgar (US Regulatory) | Allos Therapeutics Inc - Amended Statement of Beneficial Ownership (SC 13D/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 30/05/2008 | 12:15 | Edgar (US Regulatory) | Allos Therapeutics Inc - Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 29/05/2008 | 17:22 | Edgar (US Regulatory) | Allos Therapeutics Inc - Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 29/05/2008 | 16:00 | Business Wire | Allos Therapeutics Announces Closing of Public Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/05/2008 | 17:06 | Edgar (US Regulatory) | Allos Therapeutics Inc - Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 23/05/2008 | 08:25 | Edgar (US Regulatory) | Allos Therapeutics Inc - Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 23/05/2008 | 08:15 | Edgar (US Regulatory) | Allos Therapeutics Inc - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 23/05/2008 | 07:34 | Business Wire | Allos Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 19/05/2008 | 07:41 | Business Wire | Allos Therapeutics Announces Public Offering of 9,000,000 Shares of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 15/05/2008 | 07:00 | Business Wire | Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/05/2008 | 17:40 | Edgar (US Regulatory) | Allos Therapeutics Inc - Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/05/2008 | 08:30 | Business Wire | Allos Therapeutics Reports First Quarter 2008 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/05/2008 | 17:30 | Business Wire | Allos Therapeutics to Present at the Bank of America 2008 Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 29/04/2008 | 15:24 | Edgar (US Regulatory) | Allos Therapeutics Inc - Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 24/04/2008 | 17:00 | Business Wire | Allos Therapeutics to Report 2008 First Quarter Financial Results on May 7, 2008 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 22/04/2008 | 09:00 | Business Wire | Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lympho | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/02/2008 | 18:54 | Edgar (US Regulatory) | Allos Therapeutics Inc - Annual Report (10-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/02/2008 | 09:30 | Business Wire | Allos Therapeutics Reports 2007 Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 14/02/2008 | 18:52 | Edgar (US Regulatory) | Allos Therapeutics Inc - Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/02/2008 | 11:00 | Business Wire | Allos Therapeutics to Report 2007 Results on February 27, 2008 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/02/2008 | 18:23 | Edgar (US Regulatory) | Allos Therapeutics Inc - Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 29/01/2008 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 28/01/2008 | 11:00 | PR Newswire (US) | Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/01/2008 | 11:00 | PR Newswire (US) | Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Cell Lung Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/12/2007 | 11:00 | PR Newswire (US) | Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Periph | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/12/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2008 JPMorgan Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/12/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 29/11/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 BMO Capital Markets Focus on Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/11/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 Lazard Capital Markets Healthcare Investor Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/11/2007 | 19:00 | PR Newswire (US) | Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |